Sastasundarventures · risk themes across the available quarters.
Bear-case history
The B2C segment (Sastasundar) posted ₹44 crore quarterly revenue, recovering from ₹35 crore earlier. Management targets 100% growth next year to reach levels previously handed to Flipkart, but execution on customer acquisition and repeat orders remains uncertain given heavy technology investment phase.
The GST rate reduction from 12% to 5% on medicines left the company with accumulated input tax credit on inventory. Management acknowledged ₹2-3 years of working capital pressure while awaiting adjustment through higher-GST product sales. One month extra credit from pharma companies has already been utilized.
An analyst directly questioned how the business model remains defensible given everything is in public domain. Management cited 10-year relationship building with pharma companies and ₹2,000 crore equivalent cost to replicate distribution rights, plus 5 years to build technology and warehouse efficiency. However, no patent protection exists for the core model.
An analyst raised concerns about conflict between the JTO generic brand and pharmaceutical companies supplying branded medicines through the platform. Management argued the customer segments are different (price-sensitive vs branded), but the risk of strained pharma relationships remains unaddressed.